The two companies, along with 17 US health systems, will collectively take a $320 million stake in Truveta, with Regeneron ...

Each year at the JP Morgan Healthcare Conference, life sciences leaders congregate in San Francisco’s Union Square to network ...

Johnson & Johnson has agreed to take over Intra-Cellular Therapies in a deal worth up to $14.6 billion – the second biopharma ...

This morning, the UK pharma group confirmed it had signed an agreement to buy privately-held IDRx for $1 billion upfront, ...

Metsera's lead asset is MET-097i, billed as an ultra-long-acting GLP-1 receptor agonist with a profile that could challenge ...

The $7.22-per-share deal for 89.8% of Sage is a 30% premium on the company's share price on Friday and is estimated by ...

Solution: EVERSANA created an AI-enabled omnichannel solution to inform and empower HCPs and patients more effectively. The ...

In October, Intellia reported phase 2 results with NTLA-2002 – which is pitching to become the first approved in vivo CRISPR ...

Drugs for metabolic diseases, vaccines, and cancer therapies feature among new product launches this year that could top $1 ...

Through a series of position papers, the EFPIA representing brandname drugmakers, self-medication group organisation AESGP, ...

Belgian biotech Galapagos is mixing things up again via a plan to split in two, separating its innovative medicines and cell ...

Now, Novartis hopes to be able to share the data with regulatory authorities in 2025, including the US FDA, in the hope of ...